Welcome!

News Feed Item

Creabilis to Present CT327 Phase 2b Data at American Academy of Dermatology (AAD) Annual Meeting

CANTERBURY, England, March 21, 2014 /PRNewswire/ --


  • Phase  2b  data  demonstrates  a  60%  reduction  in  pruritus  in  psoriatic  patients  treated  with  CT327
  • Data  analysis  also  published  in  the  Journal  of  the  American  Academy  of  Dermatology
  • Phase  2b  CT327  topline  data  in  patients  with  Atopic  Dermatitis  and  Pruritus  due  in  mid-2014

 

Creabilis Ltd, the dermatology company with the most advanced targeted topical treatment in development for chronic pruritus (itch), announces that data from its Phase 2b trial of lead compound, CT327, will be presented in The Latest in Dermatology Research Symposia at the 72nd Annual Meeting of the AAD in Denver, Colorado, USA. Professor Gil Yosipovitch, Chair of the Department of Dermatology at the Temple University School of Medicine and Director of the Temple Center for Itch, will present the data on Saturday  22  March  at  16.15pm  CST.

CT327 is a novel topical targeted treatment for chronic pruritus in diseases of dermatology, such as psoriasis and atopic dermatitis, targeting the sensory neurones implicated in the disease through the inhibition of TrkA kinase.  Chronic pruritus is an area of significant unmet need with no approved therapies. Existing anti-inflammatory therapies that have also been tried in the treatment of pruritus are often ineffective and poorly tolerated.

The presentation (Abstract #1470), "A  novel  topical  targeted  anti-pruritic  treatment  in  Phase  2b  development  for  chronic  pruritus" will focus on the debilitating nature of chronic pruritus and importance of a targeted anti-pruritic approach for its treatment. Professor Yosipovitch will also present the recent Phase 2b data using CT327 in the treatment of pruritus in 160 psoriatic patients.  In this clinical trial, patients receiving CT327 showed a statistically significant and clinically meaningful reduction in pruritus compared to blinded vehicle emollient. Pruritus was measured using a visual analogue scale (VAS), the accepted regulatory endpoint for pruritus. The reduction from baseline in pruritus VAS reached 60% for patients treated with CT327 compared to 20% for patient treated with vehicle (p<0.05). Up to 62% of patients treated with CT327 achieved at least a 50% reduction in pruritus VAS compared to 32% of patients on vehicle (p<0.05). At baseline, 69% of patients reported at least moderate pruritus (VAS > 40mm). CT327 was safe and well tolerated, with no application site reactions.  

The abstract can be accessed at http://www.aad.org/File%20Library/Unassigned/AM14-Latest-in-Derm-Abstract-Book-FINAL-Version-2.pdf

Publication  in  the  Journal  of  the  American  Academy  of  Dermatology

Creabilis also announces that it has published new results demonstrating that pruritus severity in psoriasis patients is not correlated with psoriasis disease severity in a letter to the Journal of the American Academy of Dermatology (JAAD).  

An analysis of data drawn from Creabilis' Phase 2b study of CT327 in psoriasis patients showed no correlation between baseline pruritus severity and psoriasis disease severity.

The letter can be found online at: http://www.jaad.org/article/S0190-9622(13)01012-8/fulltext

Dr  Eliot  Forster,  Chief  Executive  Officer  of  Creabilis,  commented: "Chronic pruritus is a major clinical problem with significant market potential, where no topical medicines are currently approved.  With the powerful efficacy and differentiated safety profile seen in this clinical trial, CT327 has the potential to be the first targeted topical anti-pruritic to come to market for this common condition.

"Presenting these data at such a prestigious conference and in a leading dermatology journal demonstrates the clinical significance of these data to the dermatology community. . We very much look forward to receiving the Phase 2b data in patients with pruritus in Atopic Dermatitis later this year."

Professor  Gil  Yosipovitch,  Creabilis  Scientific  Advisory  Board  Member,  said: "Chronic Pruritus has a significant impact on the quality of life of patients with Psoriasis. These data give me hope that my patients will soon have a potent topical treatment option using this targeted anti-pruritic."

Notes  to  Editors:

About  Pruritus

Chronic pruritus (itch) is a debilitating symptom of many dermatological diseases and has a significant impact on quality of life. Patients with chronic pruritus often have multiple episodes per day, scratch until bleeding, and are unable to sleep, resulting in broader socioeconomic and psychosocial problems for these patients, including impacts on school, work attendance, and depression. Pruritus is the cardinal symptom in Atopic Dermatitis and one of the most important symptoms of Psoriasis. There is no medicine currently approved for the topical treatment of chronic pruritus. A recent study found no existing treatment relieved pruritus in 45% of psoriatics.

About  Pruritus  and  CT327

CT327 inhibits the intracellular kinase of the TrkA receptor, the high affinity receptor for Nerve Growth Factor (NGF), and consequently reduces the peripheral sensitisation of sensory neurons, a process that plays a pivotal role in the pathogenesis of pruritus.

About  Creabilis 

Creabilis is a dermatology company with the most advanced targeted topical treatment in development for chronic pruritus (itch). Creabilis has delivered positive Phase 2b results for CT327 in the treatment of pruritus in psoriasis patients. CT327 was developed using Creabilis' proprietary Low Systemic Exposure (LSE) 'topical-by-design' technology that creates molecules optimized for topical applications. Planning for Phase 3 with CT327 is underway, with a clear route to market. Creabilis' pipeline also includes CT340, an IND-ready and potent narrow spectrum kinase inhibitor in development for the topical treatment of chronic pain.

Creabilis is backed by highly respected life science investors Sofinnova Partners, Neomed and AbbVie Biotech Ventures Inc., and is led by an experienced Management team. Creabilis' Corporate Headquarters and Development functions are based in the UK, with Research activities in Italy.

More information can be found at: http://www.creabilis-sa.com

Further  information:

Creabilis
Eliot Forster
Chief Executive Officer
Email: [email protected]

Consilium  Strategic  Communications
Amber Bielecka, Jessica Hodgson, Melissa Jumbo
Tel: +44(0)203-709-5700
Email: [email protected]


SOURCE Creabilis

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, will go over the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, applicatio...
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
Microsoft Azure Container Services can be used for container deployment in a variety of ways including support for Orchestrators like Kubernetes, Docker Swarm and Mesos. However, the abstraction for app development that support application self-healing, scaling and so on may not be at the right level. Helm and Draft makes this a lot easier. In this primarily demo-driven session at @DevOpsSummit at 21st Cloud Expo, Raghavan "Rags" Srinivas, a Cloud Solutions Architect/Evangelist at Microsoft, wi...
Though cloud is the future of enterprise computing, a smooth transition of legacy applications and systems is critical for seamless business operations. IT professionals are eager to start leveraging the cost, scale and other benefits of cloud, but with massive investments already in place in existing infrastructure and a number of compliance and resource hurdles, it can be challenging to move to a cloud-based infrastructure.
Containers are rapidly finding their way into enterprise data centers, but change is difficult. How do enterprises transform their architecture with technologies like containers without losing the reliable components of their current solutions? In his session at @DevOpsSummit at 21st Cloud Expo, Tony Campbell, Director, Educational Services at CoreOS, will explore the challenges organizations are facing today as they move to containers and go over how Kubernetes applications can deploy with lega...
SYS-CON Events announced today that Avere Systems, a leading provider of hybrid cloud enablement solutions, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere Systems was created by file systems experts determined to reinvent storage by changing the way enterprises thought about and bought storage resources. With decades of experience behind the company’s founders, Avere got its ...
Today most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes significant work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reducti...
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: imple...
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, will discuss how by using...
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lead...
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
The session is centered around the tracing of systems on cloud using technologies like ebpf. The goal is to talk about what this technology is all about and what purpose it serves. In his session at 21st Cloud Expo, Shashank Jain, Development Architect at SAP, will touch upon concepts of observability in the cloud and also some of the challenges we have. Generally most cloud-based monitoring tools capture details at a very granular level. To troubleshoot problems this might not be good enough.
SYS-CON Events announced today that CAST Software will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CAST was founded more than 25 years ago to make the invisible visible. Built around the idea that even the best analytics on the market still leave blind spots for technical teams looking to deliver better software and prevent outages, CAST provides the software intelligence that matter ...